Introduction
============

As one of the leading causes of death worldwide, cancer is a serious threat to public health[@b1-ott-8-1957] with approximately 14 million new cases, 8.2 million cancer-related deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 (WHO database). Cancer is a multifactorial disease that results from complex gene--gene and gene--environment interactions.[@b2-ott-8-1957] Genetically, cancer develops as a result of mutational events involving the activation of oncogenes and inactivation of tumor suppressor genes.[@b3-ott-8-1957] The role of genetic polymorphisms has been widely investigated in many tumor types, and the relationship between tumor suppressor gene polymorphisms and cancer susceptibility has been extensively studied.[@b4-ott-8-1957] In addition, several previous meta-analyses have evaluated a specific gene polymorphism and risk for all cancer types, respectively.[@b5-ott-8-1957]--[@b7-ott-8-1957]

The Wnt signaling pathway has recently been found to play a central role in human cancer development,[@b8-ott-8-1957] and Axis inhibition protein 2 (Axin2), a tumor suppressor protein, plays an important role in the Wnt signaling pathway.[@b9-ott-8-1957] The Axin2 gene contains ten coding exons spanning more than 2.5 kb at human chromosome 17q24 and encodes a protein of 843 amino acids.[@b10-ott-8-1957],[@b11-ott-8-1957] Axin2 is a negative regulator of the Wnt signaling pathway; it directs β-catenin for proteasomal degradation.[@b12-ott-8-1957] A loss of heterozygosity in the genomic locus containing Axin2[@b13-ott-8-1957] and mutations in the gene itself has been observed in certain types of cancer,[@b14-ott-8-1957]--[@b16-ott-8-1957] suggesting that Axin2 plays an important role in carcinogenesis.

Considering the vital role of Axin2 in carcinogenesis, several case--control studies have been performed to investigate the possible association between −148 C/T (Pro50Ser, rs2240308) polymorphism of Axin2 and cancer susceptibility in different neoplasms and populations.[@b17-ott-8-1957]--[@b25-ott-8-1957] However, reports on the association between this polymorphism and cancer susceptibility are inconsistent. In addition, the studies published thus far are limited by low statistical power. To shed some light on this controversy, a meticulous meta-analysis was performed to explore the association between −148 C/T polymorphism of Axin2 and cancer risk.

Materials and methods
=====================

We performed the meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.[@b26-ott-8-1957]

Publication search
------------------

To identify all eligible studies addressing the association between the Axin2 −148 C/T polymorphism and cancer risk, we systematically searched major electronic databases, including PubMed, Embase, Wanfang and CNKI. The NCBI database of genotypes and phenotypes (<http://www.ncbi.nlm.nih.gov/gap/>) was also searched for Axin2 rs2240308 to identify GWAS data. The last search was updated on May 20, 2015. The following MeSH terms and free words were used: "Axis inhibition protein 2" or "Axin2" compiled with "SNP" or "polymorphism" or "mutation" or "variant" and "tumor" or "cancer" or "carcinoma" or "malignancy". In addition, we manually searched for references to relevant published studies and review articles. No language restrictions were applied.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria for the meta-analysis were: 1) evaluation of the Axin2 −148 C/T polymorphism and cancer susceptibility; 2) case--control or cohort design; and 3) sufficient data to determine genotype distributions. Studies were excluded for the following reasons: 1) lack of control subjects; 2) non-clinical study; 3) review, abstract, or conference paper; and 4) no reported genotype distribution or allele frequency data.

Data extraction
---------------

Two investigators (Drs Zhong and Pan) extracted the required data independently from all eligible studies. The following data were collected from each study: the first author's name, year of publication, country, ethnicity, genotyping method, *P*-values from the Hardy--Weinberg equilibrium (HWE) test for the control group, and genotype frequencies among the cases and controls. Discrepancies in data collection were resolved by group discussion. If there were questions or if the details of a particular study were needed, the authors were contacted via e-mail.

Statistical analysis
--------------------

All statistical analyses were performed using Stata (ver. 11.0; StataCorp LP, College Station, TX, USA). Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between the Axin2 −148 C/T polymorphism and cancer risk in a dominant model (TT + CT vs CC), recessive model (TT vs CT + CC), and allele model (T vs C allele). In cases in which an included study made adjustments for various covariates, the most fully adjusted OR was used. Subgroup analyses were performed according to cancer type, ethnicity, and source of control. Homogeneity was tested using the Q-statistic and *I*^2^ statistic if *P*\>0.10. The Mantel-Haenszel fixed-effects model was used when no heterogeneity existed among the studies; otherwise, DerSimonian and Laird's random-effects model was used.[@b27-ott-8-1957],[@b28-ott-8-1957] HWE of the genetic frequency distributions for the controls was calculated using Pearson's chi-square test. The significance of the pooled OR was determined by a *Z*-test. Begg's and Egger's test were used to evaluate publication bias.[@b29-ott-8-1957],[@b30-ott-8-1957] A sensitivity analysis was performed by the leave-one-out procedure.[@b31-ott-8-1957] Unless otherwise stated, a *P*-value \<0.05 was considered statistically significant. Cumulative meta-analyses (CMA) and recursive CMA were performed for each polymorphism to evaluate the trend of the risk effect (ie, OR) of the allele contrast over time.[@b32-ott-8-1957] For the CMA, studies were chronologically ordered by publication year, and the risk effect was obtained at the end of each year/information step. In the recursive CMA, the relative change in pooled OR at each information step was calculated.

Results
=======

Search results
--------------

After searching the aforementioned electronic databases, a total of 815 references were obtained. Duplicate studies were excluded, leaving 690 papers. Among these, 598 papers were excluded because they did not meet our inclusion criteria. Another 83 articles were excluded because they lacked controls (n=24), had insufficient data (n=53), or did not include −148 C/T polymorphism of Axin2 (n=6). Ultimately, nine articles were included in our meta-analysis and subjected to further statistical analysis ([Figure 1](#f1-ott-8-1957){ref-type="fig"}).

Study characteristics
---------------------

[Table 1](#t1-ott-8-1957){ref-type="table"} summarizes the characteristics of the included studies. Publication year ranged from 2006 to 2014. All nine articles, including eleven studies (1,664 patients and 1,796 controls), examined −148 C/T Axin2 polymorphism and cancer risk.[@b17-ott-8-1957]--[@b25-ott-8-1957] Of the nine articles, four were from Asia,[@b18-ott-8-1957],[@b19-ott-8-1957],[@b23-ott-8-1957] three were from the People's Republic of China,[@b19-ott-8-1957],[@b23-ott-8-1957],[@b24-ott-8-1957] and one was from Japan.[@b20-ott-8-1957] The others were from western countries, one from Poland,[@b23-ott-8-1957] and three from Turkey.[@b17-ott-8-1957],[@b21-ott-8-1957],[@b22-ott-8-1957] Regarding the ethnicity of the subjects, six studies included subjects of Asian origin[@b18-ott-8-1957],[@b19-ott-8-1957],[@b23-ott-8-1957],[@b25-ott-8-1957] and five included Caucasian subjects.[@b17-ott-8-1957],[@b20-ott-8-1957]--[@b22-ott-8-1957],[@b25-ott-8-1957] Of the eleven included studies, ten used the polymerase chain reaction-restriction fragment length polymorphism technique[@b17-ott-8-1957],[@b18-ott-8-1957],[@b20-ott-8-1957]--[@b25-ott-8-1957] and one used the TaqMan method.[@b19-ott-8-1957] Of the eleven studies, two considered prostate cancer,[@b21-ott-8-1957],[@b22-ott-8-1957] three considered lung cancer,[@b17-ott-8-1957]--[@b19-ott-8-1957] two considered colorectal cancer,[@b23-ott-8-1957],[@b24-ott-8-1957] one considered head and neck cancer,[@b23-ott-8-1957] one considered ovarian cancer,[@b20-ott-8-1957] one considered astrocytoma,[@b22-ott-8-1957] and one considered papillary thyroid cancer cancer.[@b25-ott-8-1957] All the controls in the included studies were in HWE.

Quantitative synthesis
----------------------

In dominant, recessive, and allele models, no significant between-study heterogeneity was found among the included studies (*I*^2^=0.0%, *P*=0.62; *I*^2^=9.2%, *P*=0.356; and *I*^2^=5.2%, *P*=0.394, respectively), so a fixed-effects model was used to analyze the data. The pooled data indicated a significant association between −148 C/T polymorphism of Axin2 and a decreased risk of cancer using a dominant model and an allele model (OR: 0.72, 95% CI: 0.63--0.83; OR: 0.81, 95% CI: 0.73--0.90, respectively) ([Figures 2](#f2-ott-8-1957){ref-type="fig"} and [3](#f3-ott-8-1957){ref-type="fig"}). The Axin −148 C/T polymorphism was not significantly associated with cancer risk in the recessive model (OR=0.84, 95% CI 0.69--1.02) ([Figure 4](#f4-ott-8-1957){ref-type="fig"}).

Subgroup analyses
-----------------

Subgroup analyses were performed to investigate the effects of cancer type, ethnicity, and source of control. In the cancer type-specific subgroup analysis, the Axin2 −148 C/T polymorphism was associated with a decreased risk of lung cancer (dominant model, OR: 0.69, 95% CI: 0.56--0.85; recessive model, OR: 0.61, 95% CI: 0.44--0.85; and allele model, OR: 0.73, 95% CI: 0.63--0.85). When stratified by ethnicity, a significant association between the Axin2 −148 C/T polymorphism and decreased cancer risk was identified in Asians dominant model, OR: 0.68, 95% CI: 0.57--0.81; recessive model, OR: 0.75, 95% CI: 0.56--0.99; and allele model, OR: 0.76, 95% CI: 0.66--0.86. Similarly, this association was found in the population-based (PB) controls (dominant model, OR: 0.72, 95% CI: 0.60--0.88; recessive model, OR: 0.72, 95% CI: 0.53--0.98; and allele model, OR: 0.78, 95% CI: 0.68--0.90). The main results of the pooled estimates in this meta-analysis are presented in [Table 2](#t2-ott-8-1957){ref-type="table"}. In addition, we also performed a subgroup analysis in lung cancer patients ([Table 3](#t3-ott-8-1957){ref-type="table"}).

Sensitivity analysis
--------------------

To evaluate the influence of each included study, a sensitivity analysis was performed. The leave-one-out procedure was used to estimate the contribution of each study to the pooled OR value.[@b33-ott-8-1957] For all cancer types, the ORs ranged from 0.70 (95% CI: 0.61--0.81) to 0.82 (95% CI: 0.74--0.91). For lung cancer, the ORs ranged from 0.39 (95% CI: 0.21--0.73) to 0.76 (95% CI: 0.64--0.90). The statistical significance of the results was not altered when any single study was omitted. Therefore, the stability of the study was not influenced by any individual study.

Publication bias
----------------

Begg's and Egger's tests were used to evaluate publication bias. No significant evidence of publication bias was found in the dominant, recessive, or allele models (Begg's test: *P*=0.88, 0.76, and 1.00, respectively; Egger's test: *P*=0.60, 0.81, and 0.76, respectively). The shapes of the funnel plots for the association between −148 C/T polymorphism and cancer risk also revealed no evidence of obvious asymmetry in the dominant, recessive, or allele models ([Figures 5](#f5-ott-8-1957){ref-type="fig"}[](#f6-ott-8-1957){ref-type="fig"}--[7](#f7-ott-8-1957){ref-type="fig"}). In the CMA, the pooled genetic risk effect remained significant during the entire study period. However, instability in pooled OR change was seen in the recursive CMA ([Figure 8](#f8-ott-8-1957){ref-type="fig"}). Thus, an association trend exists, and more evidence is needed to draw a safe conclusion on the significance and magnitude of the effect size.

Discussion
==========

In the present meta-analysis, we investigated the association between −148 C/T polymorphism of Axin2 and cancer risk. Our results indicate an association between −148 C/T polymorphism and a decreased risk of cancer in the dominant, recessive, and allele models. A subgroup analysis revealed that −148 C/T polymorphism was associated with a decreased risk of lung cancer in all models and prostate cancer in the dominant model, while colorectal and other cancers were unrelated to −148 C/T polymorphism of Axin2. Ethnicity-based investigations revealed that the dominant, recessive, and allele models of −148 C/T in Asians contributed to a decreased risk of cancer. Moreover, when data were stratified by the source of control, there was an association between subgroup and PB controls in all models. A significant association was found in all lung cancer subgroups, and data were grouped by ethnicity (Caucasian and Asian), sex, and smoking status.

It was previously reported that the Axin2 −148 C/T genotype is associated with a decreased risk of cancer. One study suggested that this polymorphism could be used as a marker to identify individuals with a low risk of developing lung cancer.[@b18-ott-8-1957] A recent study reported an association between −148 C/T genotype and a low risk of prostate cancer.[@b23-ott-8-1957] Based on our meta-analysis, we speculate that −148 C/T polymorphism of Axin2 alters transcription of the gene, thereby decreasing the risk of the onset of cancer. However, such an association has not been reported in colorectal cancer,[@b18-ott-8-1957],[@b24-ott-8-1957] head and neck cancer,[@b18-ott-8-1957] ovarian cancer,[@b20-ott-8-1957] astrocytoma,[@b2-ott-8-1957],[@b22-ott-8-1957] or papillary thyroid cancer.[@b25-ott-8-1957] This may be partly explained by the limited number of studies conducted and the small sample size included in each study.

The Axin2 gene is known to have a single nucleotide polymorphism (SNP) at codon 50 encoding either proline (CCT) or serine (TCT). To date, the biological mechanism linking Axin2 to carcinogenesis has not been clarified. Axin2 is a multi-domain scaffold protein that plays an important role in various biological processes, including Wnt/β-catenin signaling.[@b33-ott-8-1957],[@b34-ott-8-1957] Aberrant Wnt/β-catenin signaling occurs in various cancers.[@b35-ott-8-1957] A large complex of Axin, adenomatous polyposis coli, β-catenin, GSK3β, and several other proteins regulates Wnt signaling through the regulation of β-catenin cytoplasmic localization.[@b16-ott-8-1957],[@b36-ott-8-1957] The predicted functional domains of the Axin2 protein include the regulator of G protein signaling (RGS) domain (amino acids 81--200), the GSK3 interaction domain (amino acids 327--413), and the β-catenin binding site (amino acids 413--476).[@b18-ott-8-1957] The RGS domain has been reported to function as the adenomatous polyposis coli-binding site. The RGS domain (amino acids 81--200) participates in Axin2 tumor suppressor functions.[@b37-ott-8-1957] The location of the Axin2 rs2240308 SNP at codon 50 is extremely close to the RGS domain.[@b18-ott-8-1957] Thus, genetic variation in Axin2 may affect the risk of developing cancer.

During the review process of this manuscript, a meta-analysis evaluating rs2240308 and the risk of cancer was published;[@b38-ott-8-1957] however, the meta-analyses in the present study provide much more information. The differences between this recently published report and our study are as follows: 1) we included more studies that met our inclusion and exclusion criteria; thus, the results might be more accurate; 2) the previous meta-analysis only performed a subgroup analysis based on ethnicity and cancer type; we performed not only a subgroup analysis stratified by ethnicity and cancer type but also lung cancer-specific subgroup analyses by ethnicity, sex, and smoking status in PB or hospital-based controls; and 3) we performed additional CMA and recursive CMA to investigate the trend and stability of effect sizes as evidence accumulated. The CMA for Axin2 showed a consistent and significant trend toward an association as evidence from published studies accumulated. The recursive CMA indicated instability in the relative change in risk effects, and therefore, more evidence is needed to claim or deny the existence of an association between the variants and cancer.

Some limitations of this meta-analysis should be addressed. First, the meta-analysis was based on unadjusted risk estimates. A lack of data on possible effect modifiers (eg, sex, age, and clinical manifestations) in the included studies may have affected the identification of associations with disease. Second, sampling variability within each study may be a confounding factor in determining the effect of genetic variation on cancer susceptibility. Third, the sample size was relatively small, restricting the power and subgroup analysis of this meta-analysis. Fourth, the etiology of common disorders is multifactorial and involves complex epistemic and gene--environment interactions. Nevertheless, this is the first meta-analysis to explore the relationship between −148 C/T polymorphism of Axin2 and cancer risk. The major findings of this meta-analysis were a lack of heterogeneity and no publication bias.

Conclusion
==========

In summary, the present meta-analysis provides clear evidence showing that −148 C/T polymorphism of Axin2 contributes to a decreased risk of cancer, especially lung cancer, in Asians and PB controls. However, studies of gene--gene and gene--environment interactions should be considered in the future to obtain a more comprehensive understanding of the association between the Axin2 −148 C/T polymorphism and cancer risk. A future study that consists of a larger sample size is required to further evaluate this association.
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![Forest plot of the association between the Axin2 −148 C/T polymorphism (dominant model) and cancer risk.\
**Abbreviations:** Axin2, Axis inhibition protein 2; OR, odds ratio; CI, confidence interval.](ott-8-1957Fig2){#f2-ott-8-1957}

![Forest plot of the association between the Axin2 −148 C/T polymorphism (allele model) and cancer risk.\
**Abbreviations:** Axin2, Axis inhibition protein 2; OR, odds ratio; CI, confidence interval.](ott-8-1957Fig3){#f3-ott-8-1957}

![Forest plot of the association between the Axin2 −148 C/T polymorphism (recessive model) and cancer risk.\
**Abbreviations:** Axin2, Axis inhibition protein 2; OR, odds ratio; CI, confidence interval.](ott-8-1957Fig4){#f4-ott-8-1957}

![Funnel plots of Axin2 −148 C/T polymorphism in the dominant model.\
**Abbreviations:** Axin2, Axis inhibition protein 2; SE, standard error of the mean.](ott-8-1957Fig5){#f5-ott-8-1957}

![Funnel plots of Axin2 −148 C/T polymorphism in the recessive model.\
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![Funnel plots of Axin2 −148 C/T polymorphism in the allele model.\
**Abbreviations:** Axin2, Axis inhibition protein 2, SE, standard error of the mean.](ott-8-1957Fig7){#f7-ott-8-1957}

![(**A**) Cumulative meta-analysis for the allele contrast. The pooled OR with the corresponding 95% CI at the end of each year/information step is shown. (**B**) Recursive cumulative meta-analysis for the allele contrast. The relative change in the random-effects pooled OR in each information step (OR in the next year/OR in the current year) is shown.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](ott-8-1957Fig8){#f8-ott-8-1957}

###### 

Characteristics of the studies included in this meta-analysis

  Author                                    Year   Country                      Ethnicity   Source of control   No (cases/controls)   Genotyping method   Tumor type                 Case   Control   pHWE                    
  ----------------------------------------- ------ ---------------------------- ----------- ------------------- --------------------- ------------------- -------------------------- ------ --------- ------ ----- ----- ---- ------
  Kanzaki et al[@b18-ott-8-1957]            2006   Japan                        Asian       PB                  160/110               PCR-RFLP            Lung cancer                81     71        8      42    52    15   0.86
  Kanzaki et al[@b18-ott-8-1957]            2006   Japan                        Asian       PB                  113/110               PCR-RFLP            Colorectal cancer          54     44        15     42    52    15   0.86
  Kanzaki et al[@b18-ott-8-1957]            2006   Japan                        Asian       PB                  63/110                PCR-RFLP            Head and neck cancer       25     29        9      42    52    15   0.86
  Gunes et al[@b17-ott-8-1957]              2009   Turkey                       Caucasian   NR                  100/100               PCR-RFLP            Lung cancer                45     47        8      32    52    16   0.5
  Gunes et al[@b22-ott-8-1957]              2010   Turkey                       Caucasian   HB                  100/100               PCR-RFLP            Astrocytoma                39     45        16     32    52    16   0.5
  Pinarbasi et al[@b21-ott-8-1957]          2011   Turkey                       Caucasian   HB                  84/100                PCR-RFLP            Prostate cancer            30     35        19     34    48    18   0.88
  Naghibalhossaini et al[@b24-ott-8-1957]   2012   Iran                         Caucasian   NR                  110/179               PCR-RFLP            Colorectal cancer          34     57        19     55    98    26   0.10
  Mostowska et al[@b20-ott-8-1957]          2014   Poland                       Caucasian   HB                  258/282               PCR-RFLP            Ovarian cancer             67     115       46     71    146   65   0.55
  Ma et al[@b23-ott-8-1957]                 2014   People's Republic of China   Asian       PB + HB             103/100               PCR-RFLP            Prostate cancer            61     31        11     39    52    9    0.15
  Liu et al[@b25-ott-8-1957]                2014   People's Republic of China   Asian       PB                  520/555               TaqMan              Lung cancer                235    216       47     211   255   67   0.46
  Liu et al[@b25-ott-8-1957]                2014   People's Republic of China   Asian       HB                  53/50                 PCR-RFLP            Papillary thyroid cancer   27     24        2      17    29    4    0.08

**Abbreviations:** No, number; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium; PB, population based; NR, no report; HB, hospital based.

###### 

Subgroup analysis of the studies included in this meta-analysis

  Subgroup             No of studies   TT + TC vs CC       TT vs TC + TC   T vs C                                         
  -------------------- --------------- ------------------- --------------- ------------------- ------ ------------------- ------
  All                  11              0.72 (0.63--0.83)   0.00            0.84 (0.69--1.02)   0.08   0.81 (0.73--0.90)   0.00
  Cancer type                                                                                                             
   Lung cancer         3               0.69 (0.56--0.85)   0.00            0.61 (0.44--0.85)   0.03   0.73 (0.63--0.85)   0.00
   Colorectal cancer   2               0.83 (0.57--1.20)   0.32            1.11 (0.68--1.82)   0.69   0.94 (0.73--1.21)   0.63
   Prostate cancer     2               0.62 (0.41--0.93)   0.02            1.28 (0.73--2.28)   0.39   0.83 (0.62--1.12)   0.22
   Other               4               0.76 (0.64--0.91)   0.00            0.89 (0.66--1.21)   0.47   0.85 (0.72--1.00)   0.05
  Ethnicity                                                                                                               
   Caucasian           5               0.80 (0.64--1.01)   0.06            0.93 (0.71--1.23)   0.62   0.89 (0.76--1.03)   0.12
   Asian               6               0.68 (0.57--0.81)   0.00            0.75 (0.56--0.99)   0.04   0.76 (0.66--0.86)   0.00
  Source of control                                                                                                       
   PB                  4               0.72 (0.60--0.88)   0.00            0.72 (0.53--0.98)   0.03   0.78 (0.68--0.90)   0.00
   HB                  4               0.82 (0.61--1.09)   0.16            0.96 (0.69--1.33)   0.80   0.90 (0.75--1.09)   0.29

**Abbreviations:** No, number; OR, odds ratio; PB, population based; HB, hospital based.

###### 

Subgroup analysis of the studies in lung cancer

  Subgroup         No of studies   TT + TC vs CC       TT vs TC + TC   T vs C                                         
  ---------------- --------------- ------------------- --------------- ------------------- ------ ------------------- ------
  Lung cancer      3               1.65 (1.18--2.31)   0.00            1.45 (1.18--1.79)   0.00   1.36 (1.17--1.59)   0.00
  Ethnicity                                                                                                           
   Asian           2               0.64 (0.44--0.91)   0.01            0.60 (0.41--0.87)   0.00   0.74 (0.60--0.91)   0.01
   Caucasian       1               0.45 (0.43--0.85)   0.00            0.58 (0.32--1.02)   0.00   0.63 (0.42--0.96)   0.00
  Sex                                                                                                                 
   Male            2               0.62 (0.41--0.95)   0.03            0.42 (0.20--0.87)   0.02   0.65 (0.48--0.89)   0.01
   Female          2               0.55 (0.34--0.90)   0.02            0.32 (0.12--0.85)   0.02   0.58 (0.40--0.84)   0.00
  Smoking status                                                                                                      
   Smoking         2               0.64 (0.41--0.99)   0.04            0.38 (0.17--0.84)   0.02   0.65 (0.47--0.90)   0.01
   Non-smoking     2               0.60 (0.39--0.91)   0.02            0.37 (0.16--0.89)   0.03   0.59 (0.41--0.83)   0.00

**Abbreviations:** No, number; OR, odds ratio.
